TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Average PT from Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been given an average rating of “Moderate Buy” by the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $40.67.

TGTX has been the topic of a number of research analyst reports. The Goldman Sachs Group lifted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Finally, StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $30.90 on Friday. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a fifty day moving average price of $31.28 and a two-hundred day moving average price of $27.21. The firm has a market cap of $4.81 billion, a P/E ratio of -308.97 and a beta of 2.26.

Insider Buying and Selling

In related news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NBC Securities Inc. increased its stake in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 485 shares during the last quarter. Blue Trust Inc. grew its stake in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in TG Therapeutics in the 3rd quarter worth about $53,000. Values First Advisors Inc. acquired a new position in TG Therapeutics in the 3rd quarter worth about $58,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.